The new Alzheimer's drug, donanemab, has been deemed not cost-effective for the NHS by the health spending watchdog in England. Despite its potential to slow cognitive decline, the drug's high cost does not justify its benefits.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing